American Academy of Neurology (AAN)
75^th Annual Meeting in Boston, Mass. (April 22-28, 2023)

• Early-life social determinants of SCA6 age at onset, severity, and progression.
  

  Chen T, Casey H, Lin C-Y, Boyle T, Schmahmann J, L'Italien G, et al.

• Gambling associated risk-taking decision in cerebellar ataxia.
  

  Lai R-Y, Desai N, Amlang C, Lin C-Y, Chen T, Minyetty M, et al.

• Cognitive function remains associated with global functional impairment in profound dementia due to Alzheimer's disease and dementia with Lewy bodies.
  

  Rampalli I, Pavlik V, Yu M, Bishop J, Lin C

• Precision neurology for dementia.
  

  Shulman J, Vanegas-Arroyave N, Fong J, Elsea S, Lin C, Saade H, et al.

2022 Alzheimer's Association International Conference (AAIC)
San Diego, Calif. (July 30 - Aug. 4, 2022)

• Reduced vascular disease mortality associated with improved 5-year survival in an AD cohort followed for 25 years.
  [Platform Presentation]
  

  Pavlik VN

American Neurological Association (ANA)
146^th Annual Virtual Meeting (Oct. 14-19, 2021)

• The implication of pyramidal signs in multiple system atrophy.
  [Previously Presented]
  

  Lin CY, Viswanathan A, Chen TX, Kuo SH

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021)

• Distinct impulsive traits in cerebellar ataxia and Parkinson's disease.
  

  Chen TX, Lin CY, Aumann M, Claassen D, Kuo SH

• The implication of pyramidal signs in multiple system atrophy.
  

  Lin CY, Viswanathan A, Chen TX, Kuo SH

2021 Alzheimer's Association International Conference (AAIC)
Virtual Meeting (July 26-30, 2021)

• U.S. POINTER: Lessons learned about delivery of a multi-domain lifestyle intervention during the COVID-19 pandemic.
  

  Baker LD, Espeland MA, Whitmer RA, Kivipelto M, Antkowiak S, Chavin M, et al.

American Academy of Neurology (AAN)
Virtual 2021 Annual Meeting (April 17-22, 2021)

• The implication of upper motor neuron burden in multiple system atrophy.
  

  Kuo SH, Viswanathan A, Chen TX, Lin CY

• Cerebellar Impulsivity-Compulsivity Assessment (CIA): A scale to measure impulsive and compulsive behaviors in cerebellar disorders.
  

  Lin CY, Desai NA, Freedman S, Chen TX, Viswanathan A, Korrapati K, et al.

• Corticobasal degeneration and auditory hallucination.
  

  Lin CY, Viswanathan A, Kang UJ, Vonsattel JP

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 12-16, 2020)

• Impulsivity in cerebellar ataxias: Testing the cerebellar reward hypothesis in humans.
  [Previously Presented]
  

  Amokrane N, Viswanathan A, Freedman S, Yang CY, Kuo SH, Lin CY

2020 Alzheimer's Association International Conference (AAIC)
Virtual Meeting (July 27-31, 2020)

• US-POINTER (USA).
  [Platform Presentation]
  

  Baker LD, Espeland MA, Kivipelto M, Whitmer RA, Snyder HM, Carrillo MC, et al.

• Different profiles of cognitive deficits predict progression rate in probable AD.
  

  Sood A, Pavlik VN, Darby E, Chan W, Doody R

American Academy of Neurology (AAN)
72^nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)

• Impulsivity in cerebellar ataxias: Testing the cerebellar reward hypothesis in humans.
  

  Amokrane N, Viswanathan A, Freedman S, Yang CY, Kuo SH, Lin CY

2019 Alzheimer's Association International Conference (AAIC)
Los Angeles, Calif. (July 14-18, 2019)

• Cholinesterase inhibitors have a disease modifying effect in AD relative to CHRFAM7A genotype suggesting an a7NAChR dependent mechanism.
  

  Szigeti K, Chen Z, Ouf A, Reisch J, Pavlik V, Wilding G

American Academy of Neurology (AAN)
71^st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)

• Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies.
  [Platform Presentation]
  

  Klein G, Delmar P, Rehal S, Adjelkovic M, Abi-Saab D, Bullain SS, et al.

• Baseline characteristics from a phase III trial of crenezumab in early (prodromal-to-mild) Alzheimer's disease (CREAD).
  

  Sink S, Ostrowitzki S, Millar L, Warren F, Lin HC, Smith J, et al.

14^th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Lisbon, Portugal (March 26-31, 2019)

• Temporal trends in mortality in an AD clinical cohort.
  

  Pavlik VN, Darby E, Kass JS

2018 Alzheimer's Association International Conference (AAIC)
Chicago, Ill. (July 22-26, 2018)

• Update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the Marguerite Road Study in patients with mild Alzheimer's disease (AD) after approximately two years of study duration.
  

  Abi-Saab D, Andjelkovic M, Pross N, Delmar P, Voyle N, Klein G, et al.

• Update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the Scarlet Road Study in patients with prodromal Alzheimer's disease after approximately two years of study duration.
  

  Andjelkovic M, Abi-Saab D, Delmar P, Pross N, Voyle N, Klein G, et al.

• Concord-AD: An international network of cohorts for better understanding of Alzheimer's disease.
  

  Burham, SC, Colom PM, Datigues JF, Doody R, Hansson O, et al.

• Twenty-four month amyloid PET results of the gantenerumab high dose open label extension studies.
  

  Klein G, Delmar P, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, et al.

• Baseline characteristics from a phase 3 trial of crenezumab in prodromal to mild Alzheimer's disease (CREAD).
  

  Lin H, Ostrowitzki S, Sink KM, Millar L, Warren F, Smith J, et al.

• Twenty year trends in proportional mortality in a probable AD cohort.
  

  Pavlik VN, Darby E, Kass JS

• The effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (CSF) in the Marguerite Road Study.
  

  Voyle N, Abi-Saab D, Klein G, Hofmann C, Delmar P, Pross N, et al.

Columbia University College of Physicians and Surgeons
1^st International Tremor Congress in New York City, N.Y. (May 11-12, 2018)

• Serum anti-gliadin antibodies in cerebellar ataxias: A systematic review and meta-analysis.
  [Previously Presented]
  

  Lin CY, Wang MJ, Tse W, Pinotti R, Green PH, Alaedini A, et al.

American Academy of Neurology (AAN)
70^th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)

• Higher dose gantenerumab leads to significant reduction in amyloid plaque burden - Results for the Marguerite and Scarlet Road open label extension studies.
  

  Klein G, Delmar P, Hofmann C, Adjelkovic M, Abi-Saab D, Milosavljevic-Ristic S, et al.

• Serum anti-gliadin antibodies in cerebellar ataxias: A systematic review and meta-analysis.
  

  Lin CY, Wang MJ, Tse W, Pinotti R, Green PH, Alaedini A, et al.

• Wernicke encephalopathy masquerading as a right middle cerebral artery territory infarction.
  

  Lin CY, Yoo JY, Doshi A, Colman R

• Validation of a pre-diagnostic progression rate used to predict post-diagnostic change on common Alzheimer's disease outcome measures.
  

  Pavlik V, Chan W, Darby E

2017 Alzheimer's Association International Conference (AAIC)
London, United Kingdom (July 15-20, 2017)

• Predictors of atypical antipsychotic treatment in an AD clinical population.
  

  Pavlik VN, Bishop JS, Glosch C, Yu M, Darby E, Starks S, et al.

• Cohort effects in progression rate in a clinical registry of Alzheimer's patients accrued from 1995-2010.
  

  Pavlik VN, Chan W, Darby E, Kass JS

International Neuropsychological Society (INS)
45^th Annual Meeting in New Orleans, La. (Feb. 1-7, 2017)

• Longitudinal cognitive asymmetry and decline in Alzheimer's disease patients.
  

  Alverson WA, Massman PJ, Doody RS

2016 Alzheimer's Association International Conference (AAIC)
Toronto, Canada (July 22-28, 2016)

• Advancing therapeutics for neuroinflammation in Alzheimer's disease: Clinical development considerations.
  

  Margolin RA, Schneider LS, Cutter GR, Breitner JCS, Doody RS, Landreth G, et al.

American Academy of Neurology (AAN)
68^th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)

• PRISM II: Effectiveness of dextromethorphan 20 mg/quinidine 10 mg (Nuedexta®) for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Combined results of a multicenter open-label study.
  

  Siffert J, Hammond F, Alexander D, Cutler A, D'Amico S, Doody R, et al.

• Randomized, double-blind, placebo-controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer's disease: Phase 3 study design.
  [Oral Presentation]
  

  Viglietta V, O'Gorman J, Williams L, Tian Y, Sandrock A, Doody R, et al.

Society for Neuroscience (SFN)
45^th Annual Meeting in Chicago, Ill. (Oct. 17-21, 2015)

• Validation of olfactory identification deficit as a biomarker of Alzheimer's disease.
  

  Lazar E, Woodward M, Amrutkar C, Hagemeier J, Shah H, Benedict R, et al.

2015 Alzheimer's Association International Conference (AAIC)
Washington, DC (July 18-23, 2015)

• Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Comparison of patient-reported ratings to those of caregiver proxies in a 12-week open-label trial (PRISM II).
  

  Doody RS, Cutler AJ, D'Amico S, Shin P, Ledon F, Yonan C, et al.

• Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Examination of CNS-LS outcomes in a 12-week open-label trial (PRISM II).
  

  Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al.

• Dextromethorphan/quinidine for treatment of pseudobulbar affect in patients with dementia: Treatment effects by concomitant antidepressant use in a 12-week open-label trial (PRISM II).
  [Platform Presentation]
  

  Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al.

• TTP488 path to registration: Leveraging enrichment strategies.
  

  Sabbagh MN, Burstein A, Grimes I, Valcarce C, Doody RS, Sano M, et al.

• TTP488: From futile to fast track.
  

  Sabbagh MN, Burstein A, Grimes I, Valcarce C, Rose E, Doody RS, et al.

North American Primary Care Research Group (NAPCRG)
2015 Practice-Based Research Network Conference in Bethesda, Md. (June 29-30, 2015)

• Selection of resources from a vaccination standing order program toolkit during a randomized trial to improve vaccination rates in a PBRN.
  

  Brown A, Pavlik V, Zimmerman R, Danek L, Lacour-Chestnut F, Lateef M, et al.

• Content of patient instructions section of an EHR generated after visit summary affects patient satisfaction.
  

  Pavlik V, Nash SG, Laufman L

American Academy of Neurology (AAN)
67^th Annual Meeting in Washington, DC (April 18-25, 2015)

• Validation of olfactory deficit as a biomarker of Alzheimer's disease.
  

  Amrutkar C, Woodward M, Shah H, Benedict R, Rajakrishnan S, Doody R, et al.

• PRISM II: An open-label study to assess the safety, tolerability, and effectiveness of dextromethorphan 20 mg/quinidine 10 mg for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Results from the Alzheimer's disease/dementia cohort.
  

  Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al.

North American Primary Care Research Group (NAPCRG)
42^nd Annual Meeting in New York, N.Y. (Nov. 21-25, 2014)

• Provider survey of attitudes toward and uses of an electronic after visit summary.
  

  Almutairi A, Nash SG, Laufman LE, Pavlik V

• Patterns of glycemic control with exclusive oral hypoglycemic agent use in a community health care setting.
  

  Vaughan E, Aggarwal A, Pavlik V

American Neurological Association (ANA)
139^th Annual Meeting in Baltimore, Md. (Oct. 12-14, 2014)

• WIP safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer's disease/dementia: PRISM-II.
  

  Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al.

• Antioxidant biomarkers predict annualized change in MMSE score in MCI and AD patients in the TARCC cohort.
  

  Majid T, Chan W, Darby E, Pavlik V, Doody R

2014 Alzheimer's Association International Conference (AAIC)
Copenhagen, Denmark (July 12-17, 2014)

• Comparing recruitment among geographic regions in multinational Alzheimer's disease clinical trials.
  

  Grill JD, Raman R, Ernstrom K, Dowsett S, Chen Y-F, Liu-Seifert H, et al.

• Regional variation in Alzheimer's disease progression in a clinical trial setting.
  

  Henley DB, Dowsett SA, Chen Y-F, Liu-Seifert H, Grill JD, Doody R, et al.

North American Primary Care Research Group (NAPCRG)
2014 Practice-Based Research Network Conference in Bethesda, Md. (June 30 - July 1, 2014)

• Development of a codebook to describe the content of the patient instructions section of an EHR-generated after visit summary.
  

  Pavlik V, Campbell-Voytal K, Nash SG, Laufman L, Neale V

International Neuropsychological Society (INS)
42^nd Annual Meeting in Seattle, Wash. (Feb. 12-15, 2014)

• Progression and stability of cognitive asymmetry in a large sample of Alzheimer's disease patients.
  

  Alverson WA, Massman PJ, Grabyan JM, Doody RS

2013 Alzheimer's Association International Conference (AAIC)
Boston, Mass. (July 13-18, 2013)

• A study to assess the safety, tolerability, and effectiveness of Nuedexta (dextromethorphan 20 mg/quinidine 10 mg) in the treatment of pseudobulbar affect (PBA) [PRISM II].
  

  Doody R, Cutler A, D'Amico S, Zorowitz R, Alexander D, Hammond F, et al.

• Ordered subset analysis CNV association with Alzheimer's disease AAO phenotypes.
  

  Szigeti K, Trummer B, Lal D, Yan L, Song L, Doody R

American Academy of Neurology (AAN)
65^th Annual Meeting in San Diego, Calif. (March 16-23, 2013)

• Examining anti-dementia drug persistence in Alzheimer's disease (AD) patients.
  

  Biernot J, Darby E, Chan W, Pavlik V, Doody R

International Neuropsychological Society (INS)
41^st Annual Meeting in Montreal, Waikoloa, Hawaii (Feb. 6-9, 2013)

• A simple method for enhancing prediction of longitudinal decline in instrumental activities of daily living in Alzheimer's patients.
  

  Grabyan JM, Massman PJ, Alverson W, Doody RS

• Improving predictive validity of the Clinical Dementia Rating Scale for functional outcomes.
  

  Lowe DA, Balsis S, Miller T, Benge JF, Doody RS.

National Academy of Neuropsychology (NAN)
32^nd Annual Meeting in Nashville, Tenn. (Nov. 7-10, 2012)

• Mexican American normative references on tasks of memory and language: The Texas Mexican American normative studies.
  

  Edwards M, Balldin V, Hall J, Strutt A, Pavlik V, Marquez de la Plata C, et al.

• Normative data for Mexican American on tasks of executive and physiometric functions: The Texas Mexican American normative studies.
  

  Hall J, Edwards M, Balldin V, Strutt A, Pavlik V, Marquez de la Plata C, et al.

• Normative performance on the RBANS in a multi-ethnic bilingual cohort: The Texas Mexican American normative studies.
  

  Hobson Balldin V, Menon C, Younes S, Hall J, Strutt A, Pavlik V, et al.

American Neurological Association (ANA)
137^th Annual Meeting in Boston, Mass. (Oct. 7-9, 2012)

• Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease.
  [Platform Presentation]
  

  Szigeti K, Lal D, Li Y, Doody RS, Yan L

Alzheimer's Association International Conference (AAIC)
Annual Meeting in Vancouver, British Columbia, Canada (July 14-19, 2012)

• Premorbid IQ and intrinsic progression rate explain substantial variance in observed progression of Alzheimer's disease (AD) on multiple measures.
  

  Doody R, Chan W, Pavlik V, Rountree S, Massman P

• Factors influencing time to nursing home placement in persons with probable Alzheimer's disease.
  

  McGee JS, Nguyen A, Darby E, Chan W, Pavlik V, Doody R

• Factors that influence long term care placement in an Alzheimer disease cohort.
  

  Rountree S, Chan W, Pavlik V, Doody R

• Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease.
  

  Szigeti K, Li Y, Shaw C, Sheffer I, Sule N, Powell S, et al.

• Dimebon in Alzheimer's disease: Summary and contract of three efficacy trials.
  

  Winblad B, Doody R, Cummings J, Tariot P, Sano M, Aisen P, et al.

American Society of Hypertension (ASH)
27^th Annual Scientific Meeting and Exposition in New York, N.Y. (May 19-22, 2012)

• Pooled analysis of three cluster randomized hypertension control trials in African-Americans.
  

  Pavlik V, Chan W, Hyman D, Feldman P, Tobin J, Ogedegbe G, et al.

International Neuropsychological Society (INS)
40^th Annual Meeting in Montreal, Quebec, Canada (Feb. 15-18, 2012)

• Plasma cortisol does not predict rate of cognitive decline in Alzheimer's patients.
  

  Grabyan JM, Massman PJ, Porter B, Doody RS

• Amnestic MCI, sleep disturbance, and cognitive functioning.
  

  McGee JS, Darby EJ, Biernot J, Doody RS

2011 International Conference on Alzheimer's Disease (ICAD)
Paris, France (July 16-21, 2011)

• Serum granulocyte colony stimulating factor and Alzheimer's disease.
  

  Barber R, O'Bryant S, Reisch J, Doody R, Fairchild T, Adams P, et al.

• The impact of depression on cognition varies by APOE4 status.
  

  Dentino A, Hall J, Barber R, Doody R, Royall D, O'Bryant S

• Biomarkers associated with cardiovascular risk in the Texas Alzheimer's Disease Research and Care Consortium (TARCC) Cohort: LpPla2 and homocysteine.
  

  Doody R, Chan W, Ballantyne C, Pavlik V, Barber R, O'Bryant S, et al.

• Inflammatory biomarkers in the Texas Alzheimer's Research and Care Consortium (TARCC) Cohort.
  

  Doody R, Chan W, Barber R, Ballantyne C, Pavlik V, O'Bryant S, et al.

• Plasma sphingomyelin is associated with cognitive progression in Alzheimer's disease.
  

  Mielke M, Haughey N, Bandaru VVR, Weinberg D, Zaidi N, Pavlik V, et al.

• Refinement and expansion of the Texas Alzheimer's research consortium serum-based diagnostic algorithm for Alzheimer's disease.
  

  O'Bryant S, Xiao G, Barber R, Hall J, Doody R, Reisch J, et al.

• A serum protein-based algorithm for the detection of Alzheimer's disease.
  

  O'Bryant S, Xiao G, Robert B, Hall J, Doody R, Reisch J, et al.

• Racial/ethnic group differences in the association of APOE ε4 genotype and visuospatial test performance in a non-demented sample.
  

  Pavlik V, Massman P, Rustveld L, Doody R

• Factors that influence survival in Alzheimer's patients.
  

  Rountree S, Chan W, Pavlik V, Darby E, Doody R

• The cognitive correlates of functional status: a new approach to dementia.
  

  Royall DR, Doody R, Barber R, Palmer R, O'Bryant S, Reisch J, et al.

• Genome-wide association scan replication for biomarker endophenotypes of Alzheimer's disease.
  

  Wilhelmsen K, Chasse S, Griffin N, Diaz-Arrastia R, Barber R, Royall D, et al.

• Developing and validating of diagnostic algorithm for Alzheimer's disease.
  

  Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, et al.

American Academy of Neurology (AAN)
63^rd Annual Meeting in Honolulu, Hawaii (April 9-16, 2011)

• Efficacy and safety of donepezil 23 mg/day in patients with moderate-to-severe Alzheimer's disease with concomitant memantine use.
  

  Doody RS, Ramos H, Faison W, Zou H

• Differences in the association of peripheral insulin and cognitive function in non-diabetic ad cases and normal controls.
  

  Pavlik V, Massman P, Ballantyne C, Barber R, Doody RS

International Neuropsychological Society (INS)
39^th Annual Meeting in Boston, Mass. (Feb. 2-5, 2011)

• Differential recall of nouns and verbs in patients with probable Alzheimer's disease (AD).
  

  Havins W, Harika L, Massman PJ, Doody RS

• Cognitive reserve as a moderator for the relationship between depression and cognitive functioning in Alzheimer's disease.
  

  Havins WN, Agbayani KA, Massman PJ, Doody RS

• Cortisol levels in Alzheimer's patients are related to premorbid functioning and rate of progression.
  

  Massman PJ, Burrows C, Hall J, Doody RS

2010 International Conference on Alzheimer's Disease (ICAD)
Honolulu, Hawaii (July 10-15, 2010)

• An inflammatory endophenotype of Alzheimer's disease.
  

  Barber R, Xiao G, O'Bryant S, Saunders J, Reisch J, Doody R, et al.

• Presence of cardiovascular disease is associated with slower cognitive decline in Alzheimer's disease in the absence of cerebrovascular pathology.
  

  Chan M, Pavlik VN, Chan W, Darby E, Khaleeq A, Doody RS

• A serum protein-based diagnostic algorithm for Alzheimer's disease.
  

  Diaz-Arrastia R, Xiao G, Reisch J, Barber R, Doody R, Fairchild T, et al.

• Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease.
  

  Doody RS, Tariot P, Cummings J, Winblad B, Selby B, Langenberg A, et al.

• Association of genetic variation in the electron transport chain and Alzheimer's disease.
  

  Huebinger RM, Wilhelmsen K, Diaz-Arrastia R, Chasse S, O'Bryant SE, Doody R, et al.

• Genome-wide association scan for biomarker endophenotypes of Alzheimer's disease.
  

  Wilhelmsen KC, Chasse SA, Gizer IR, Cameron NG, Ellis JW, Diaz-Arrastia R, et al.

American Academy of Neurology (AAN)
61^st Annual Meeting in Seattle, Wash. (April 25 - May 2, 2009)

• How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis.
  

  Benge J, Balsis S, Geraci L, Massman P, Doody R

• Age at onset and pre- morbid IQ influence early progression rates in AD.
  

  Doody R, Chan W, Pavlik V, Massman P, Darby E, Rountree S, et al.

American Heart Association
Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference in Washington, DC (April 23-25, 2009)

• Systematic bias in blood pressure measurement between health care systems - Implications for quality of care research.
  

  Pavlik V, Greisinger AJ, Hyman DJ

International Neuropsychological Society (INS)
37^th Annual Meeting in Atlanta, Ga. (Feb. 11-14, 2009)

• Significance of the apolipoprotein E ε2 allele in Alzheimer's patients' memory functioning.
  

  Massman P, Doody RS

2008 International Conference on Alzheimer's Disease (ICAD)
Chicago, Ill. (July 26-31, 2008)

• Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease.
  

  Cummings J, Doody RS, Gavrilova S, Sano M, Aisen P, Seely L, et al.

• Interrater reliability between expert and nonexpert physicians in the assessment of amnestic MCI in the community setting.
  

  Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li MC, et al.

• Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study.
  

  Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, et al.

• The effects of donepezil on Alzheimer's disease progression monitored by MRI.
  

  Murthy AK, Schuff N, Suhy J, Doody RS, Goldman R

• Persistent antidementia drug treatment and survival in an Alzheimer's disease (AD) cohort.
  

  Rountree S, Pavlik V, Chan W, Doody RS

• The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype.
  

  Sparks L, Kivipelto M, Doody RS, Waters D, Jones RW, Feldman H, et al.

American Academy of Neurology (AAN)
60^th Annual Meeting in Chicago, Ill. (April 12-19, 2008)

• Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnestic MCI in the community setting.
  

  Doody RS, Ferris S, Salloway S, Meuser T, Murthy A, Li MC, et al.

• Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results.
  

  Doody RS, Gavrilova S, Aisen P, Hirmand M, Sano M

• Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study.
  

  Ferris S, Doody R, Gavrilova S, Sano M, Aisen P, Seely L

• Vitamin E use is associated with improved survival in an AD cohort.
  

  Pavlik VN, Doody RS, Rountree SD, Darby EJ

American Neurological Association (ANA)
132^nd Annual Meeting in Washington, DC (Oct. 7-10, 2007)

• Exposure to anti-dementia drugs slows clinical progression of Alzheimer's disease (AD).
  

  Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Gulley A, et al.

2^nd International Frontotemporal Dementia in ALS Research Conference
London, Ontario Canada (June 10-13, 2007)

• FTD-like cognitive and behavioral changes in ALS.
  

  Salamone AR, Witgert M, Macias A, Massman P, Bradshaw M, Mosnik D, et al.

Alzheimer's Association International Conference (AAIC)
Washington, DC (June 9-12, 2007)

• Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease.
  

  Doody R, Garrilova S, Sano M, Thomas R, Aisen P, Bachurin S, et al.

• Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics.
  

  Jones R, Doody R, Sparks DL, Feldman H, Kivipelto M, Breazna A, et al.

• Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD).
  

  Rountree SD, Pavlik VN, Chan W, Darby EJ, Doody RS

• The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly.
  

  Senanarong V, Hamphadungkit K, Poungvarin N, Cummings J, Doody R

American Academy of Neurology (AAN)
59^th Annual Meeting in Boston, Mass. (April 28 - May 5, 2007)

• Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study.
  

  Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Seely L, et al.

8^th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
Salzburg, Austria (March 14-18, 2007)

• Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe).
  

  Feldman H, Sparks L, Doody R, Kivipelto M, Jones R, Sovel M, et al.

American Heart Association
47^th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in Orlando, Fla. (Feb. 28 - March 3, 2007)

• Agreement between stage of change and measured behavioral endpoints: Implications for intervention design.
  

  Pavlik, VN, Hyman DJ, Goodrick KG

• Association between serum c-peptide levels and the risk of cardiovascular disease in nondiabetic individuals: Data from the National Health and Nutrition Examination Survey.
  

  Rustveld LO, Pavlik VN

10^th International Conference on Alzheimer's Disease and Related Disorders
Madrid, Spain (July 15-20, 2006)

• Predicting progression and survival in Alzheimer's disease.
  

  Doody R, Pavlik V, Massman P, Rountree S, Waring S, Darby E, et al.

• Is functional decline necessary for a diagnosis of Alzheimer's disease?
  

  Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS

• Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes.
  

  Rountree SD, Waring SC, Chan W, Darby EJ, Doody RS

• Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease.
  

  Waring SC, Paranilam JM, Doody RS, Darby EJ, Massman PJ, Chan W

American Academy of Neurology (AAN)
58^th Annual Meeting in San Diego, Calif. (April 1-8, 2006)

• Predicting progression of Alzheimer's disease.
  

  Doody R, Pavlik V, Massman P, Rountree S, Darby E, Chan W

American Heart Association/National Heart, Lung, and Blood Institute
46^th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in Phoenix, Ariz. (March 2-5, 2006)

• Association between cognitive function and metabolic control parameters in treated patients with type 2 diabetes.
  

  Pavlik VN, Hyman DJ, Balasubramanyam A, Doody R

International Neuropsychological Society (INS)
34^th Annual Meeting in Boston, Mass. (Feb. 1-4, 2006)

• Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients.
  

  Acharya D, Massman P, Doody R

• Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease.
  

  Benge J, Massman P, Jenkins R, Thornton G, Doody R

• Naming improvement with phonemic cues: Which Alzheimer's patients benefit most?
  

  Jenkins R, Massman P, Benge J, Thornton G, Doody R

• Category-letter fluency discrepancies in healthy older adults: Normative data and reliability.
  

  Thornton G, Massman P, Benge J, Jenkins R, Doody R

American Neurological Association (ANA)
130^th Annual Meeting in San Diego, Calif. (Sept. 25-28, 2005)

• Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.
  

  Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM

2^nd Alzheimer's Association International Conference (AAIC)
Washington, DC (June 9-12, 2005)

• Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease.
  

  Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM

• Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis.
  

  Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, et al.

American Academy of Neurology (AAN)
57^th Annual Meeting in Miami Beach, Fla. (April 9-16, 2005)

• Mild cognitive impairment types and their outcomes.
  

  Issa A, Rountree S, Waring S, Yeh S, Doody RS

• ADAS-Cog change rates in MMSE Strata relevant to clinical trials.
  

  Massman P, Doody RS

• Relationship of premorbid IQ and education to progression of Alzheimer's disease.
  

  Pavlik V, Doody RS, Massman P, Chan W, Yeh S

European Federation of Neurological Societies (EFNS)
8^th Congress in Paris, France (Sept. 4-7, 2004)

• Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day.
  

  Schindler R, Corey-Bloom J, Doody R, Zhang R, Leni JR, Li H

• Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
  

  Wirth Y, Doody RS, Schmitt FA, Mobius HJ, Stoffler A

9^th International Conference on Alzheimer's Disease and Related Disorders
Philadelphia, Penn. (July 17-22, 2004)

• Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits.
  

  Doody R, Pratt R, Posner H, Kumar D

• Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients.
  

  Massman P, Doody R

• Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary.
  

  Tariot P, Doody R, Peskind E, Winblad B, Reisberg B, Stoffler A, et al.

• Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease.
  

  Wirth Y, Doody RS, Schmitt FA, Mobius HJ

XXIV^th Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress
Paris, France (June 20-24, 2004)

• Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease.
  

  Wirth Y, Doody R, Schmitt F, Mobius HJ, Stoffler A

American Academy of Neurology (AAN)
55^th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003)

• Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia.
  

  Doody RS, Pratt RD, Perdomo CA, the Donepezil 307 and 308 VaD Study Groups

• Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease.
  

  Ferris SH, Schmitt FA, Doody RS, Moebius H-J, Stoeffler A, Reisberg BJ

8^th International Conference on Alzheimer's Disease and Related Disorders
Stockholm, Sweden (July 20-25, 2002)

• How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses?
  

  Clark C, Eubank D, Peskind E, Galasko D, Morris J, McKeel D, et al.

• Pathogenesis and treatment strategies for selected therapies under development.
  

  Doody RS

• Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease.
  

  Reisberg B, Mobius H, Stoffler A, Schmitt F, Doody R, Ferris S

Society for Epidemiologic Research (SER)
35^th Annual Meeting in Palm Desert, Calif. (June 19-21, 2002)

• Cognitive function and cardiovascular risk factors in adults 30-59 years old (NHANES III).
  

  Pavlik VN, Hyman DJ, Doody R

American Society of Hypertension (ASH)
17^th Annual Meeting in New York, N.Y. (May 14-18, 2002)

• Selective physician blood pressure remeasurement in the office setting may contribute to poor hypertension control.
  

  Pavlik VN, Hyman DJ, Vallbona C, Grim C

World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Denver, Colo. (April 19, 2002)

• Survival in patients with dementia from a large multi ethnic population.
  

  Waring S, Doody RS

International Neuropsychological Society (INS)
30^th Annual Meeting in Toronto, Canada (Feb. 13-16, 2002)

• Growth curve analysis of decline in instrumental activities of daily living in AD patients.
  

  Davis R, Atchison T, Massman P, Doody R

• Measurement invariance of the WAIS-R in AD among patients at higher versus lower levels of dementia severity.
  

  Davis R, Massman P, Doody R

• WAIS-R factor structure in AD: Comparison of alternative models and assessment of generalizability.
  

  Davis R, Massman P, Doody R

North American Primary Care Research Group (NAPCRG)
29^th Annual Meeting in Halifax, Nova Scotia, Canada (Oct. 13-16, 2001)

• Self-assessed knowledge of diabetes management in a low-income, minority patient population.
  

  Pavlik VN, Maldonado M, Karlsson F, Schindler J, Spann SJ

World Federation of Neurology (WFN)
Research Group on Neuroepidemiology. Regional North American Annual Meeting in Philadelphia, Penn. (May 9, 2001)

• Racial differences among patients with Alzheimer's disease from a large multi ethnic population.
  

  Waring S, Doody RS

American Academy of Neurology (AAN)
53^rd Annual Meeting in Philadelphia, Penn. (May 5-11, 2001)

• The cognitive benefits of galantamine are sustained for at least 24 months: Results of a long-term extension trial in Alzheimer's disease.
  

  Doody RS, Kershaw P

North American Primary Care Research Group (NAPCRG)
28^th Annual Meeting in Amelia Island, Fla. (Nov. 4-7, 2000)

• Improvement in systolic blood pressure control in a predominantly African-American health center.
  

  Pavlik VN, Hyman DJ, Vallbona C

7^th International Conference on Alzheimer's Disease and Related Disorders
Washington, DC (July 9-18, 2000)

• Cholinesterase inhibitors: Benefits and limitations.
  

  Doody RS

American Academy of Neurology (AAN)
52^nd Annual Meeting in San Diego, Calif. (April 29 - May 6, 2000)

• Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study.
  

  Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R

• Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden.
  

  Sumaira R, Doody R, Lai EC

American Society of Consultant Pharmacists (ASCP)
30^th Annual Meeting in St. Loius, Mo. (Nov. 10-13, 1999)

• Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety.
  

  Doody R, Geldmacher DS, Pratt RD, Perdoma CA

European College of Neuropsychopharmacology (ECNP)
12^th Congress in London, United Kingdom (Sept. 21-25, 1999)

• Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study.
  

  Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, et al.

European Neurological Society (ENS)
9^th Annual Meeting in Milan, Italy (June 5-9, 1999)

• Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration.
  

  Doody RS, Geldmacher DS, Pratt RD, Perdomo CA

American Academy of Neurology (AAN)
51^st Annual Meeting in Toronto, Canada (April 17-24, 1999)

• Does ApoE4 correlate with MRI changes in Alzheimer's disease?
  

  Azher S, Doody RS, Haykal H, Dunn JK, Liao T-Y

• Clinical benefits of donepezil: Results from a long-term phase III extension trial.
  

  Doody RS, Pratt R, Perdomo C

European College of Neuropsychopharmacology (ECNP)
11^th Congress in Paris, France (Oct. 31 - Nov. 4, 1998)

• Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials.
  

  Petit H, Doody RS, Pratt R

6^th International Conference on Alzheimer's Disease and Related Disorders
Amsterdam, The Netherlands (July 18-23, 1998)

• Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients.
  

  Doody RS, Clark C, Farlow M, Foster N, Gonzales N, Liao J, et al.

• The presence of APO E4 does not influence rate of decline in Alzheimer's disease.
  

  Kataki M, Doody RS, Liao J, Sims J

American Society of Hypertension (ASH)
13^th Annual Meeting in New York, N.Y. (May 13-16, 1998)

• Ethnic differences in 24-hour blood pressure control in treated hypertensives.
  

  Hyman DJ, Ogbonnaya K, Pavlik VN, Taylor AA, Ho K

5^th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Geneva, Switzerland (April 15-18, 1998)

• Current therapeutic standards in the treatment of Alzheimer's disease.
  

  Doody RS

• Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance?
  

  Rogers S, Mohs R, Friedhoff L, Doody RS

American Academy of Neurology (AAN)
49^th Annual Meeting in Boston, Mass. (April 15-17, 1997)

• Outcome measures in dementia trials-video CIBIC validity and reliability.
  

  Quinn JF, Benson DF, Clark C, Doody RS, Jagust W, Knopman D, et al.

American College of Neuropsychopharmacology (ACNP)
35^th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996)

• Donepezil HCI (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study.
  

  Rogers SL, Doody RS, Mohs RC, Friedhoff LT

International Behavioral Neuroscience Society (ISBN)
5^th Annual Meeting in Cancun, Mexico (May 2-5, 1996)

• Prevalence of uncontrolled hypertension in a population of Alzheimer's patients.
  

  Kashani A, Doody RS, Wayner MJ, Phelix CF

American Academy of Neurology (AAN)
48^th Annual Meeting in San Francisco, Calif. (March 23-30, 1996)

• Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment.
  

  Grundman M, Petersen R, Morris J, Ferris S, Sano M, Farlow M, et al.

• E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial.
  

  Rogers S, Doody RS, Mohs R, Friedhoff L

• Pharmacologic evidence for autonomic sudomotor dysfunction in patients with Alzheimer's disease.
  

  Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH

International Neuropsychological Society (INS)
24^th Annual Meeting in Chicago, Ill. (Feb. 14-17, 1996)

• Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials.
  

  Olin J, Clark C, Doody RS, Schmitt F, Ferris S, Morris J, et al.

Gerontological Society of America (GSA)
50^th Annual Meeting in Los Angeles, Calif. (Nov. 15-19, 1995)

• A new clinical global rating scale for Alzheimer's clinical trials.
  

  Olin J, Schneider L, Clark C, Doody RS, Ferris S, Morris J, et al.

American Neuropsychiatric Association (ANPA)
7^th Annual Meeting in Pittsburgh, Penn. (Oct. 12-15, 1995)

• Estrogen and psychomotor performance.
  

  Doody RS, Young R, Lynn P, Cooke N, Rosenfield JE

American Academy of Neurology (AAN)
47^th Annual Meeting in Seattle, Wash. (May 6-13, 1995)

• A calculated measure to predict rate of progression in Alzheimer's disease.
  

  Doody RS, Lynn P, Massman PJ

International Neuropsychological Society (INS)
23^rd Annual Meeting in Seattle, Wash. (Feb. 8-11, 1995)

• Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men.
  

  Massman PJ, Doody RS

American Academy of Neurology (AAN)
46^th Annual Meeting in Washington, DC (May 1-7, 1994)

• Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD).
  

  Doody RS, Massman PJ, Nance ML

• Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs.
  

  Massman PJ, Kreiter KT, Jankovic J, Doody RS

International Neuropsychological Society (INS)
22^nd Annual Meeting in Cincinnati, Ohio (Feb. 2-5, 1994)

• Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease.
  

  Massman PJ, Kreiter KT, Jankovic J, Doody RS

American Neurological Association (ANA)
118^th Annual Meeting in Boston, Mass. (Oct. 18-20, 1993)

• Dysfluency in the speech of AD patients.
  

  Doody RS, Massman P

• Literacy and cognition in northern Thailand.
  

  Doody RS, Welsh K

American Society of Human Genetics (ASHG)
43^rd Annual Meeting in New Orleans, La. (Oct. 5-9, 1993)

• Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia.
  

  Dunn W, Doody RS, Gopnik M, Ashizawa T

American Psychiatric Association (APA)
146^th Annual Meeting in San Francisco, Calif. (May 22-27, 1993)

• Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease.
  

  Kotrla K, Chacko R, Jhingran S, Doody RS

International Neuropsychological Society (INS)
21^st Annual Meeting in Galveston , Texas (Feb. 24-27, 1993)

• Correlates of asymmetric motor speed in Alzheimer's disease.
  

  Massman P, Doody RS

National Academy of Neuropsychology (NAN)
12^th Annual Meeting in Pittsburgh, Penn. (Nov. 5-7, 1992)

• Neuropsychological correlates of apraxia in Alzheimer's disease patients.
  

  Massman P, Doody RS

American Anthropological Association (AAA)
90^th Annual Meeting in Chicago, Ill. (Nov. 20-24, 1991)

• Positioning: Neurology and anthropology enabling practices.
  

  Doody RS

American Neurological Association (ANA)
116^th Annual Meeting in Seattle, Wash. (Sept. 28 - Oct. 2, 1991)

• Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia.
  

  Doody RS, Strittmatter WJ, Jhingran S

• Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery.
  

  Feher E, Mahurin R, Doody RS, Cooke N, Simms J, Pirozzolo F

• Positive and negative psychiatric symptoms in Alzheimer's disease.
  

  Mahurin R, Feher E, Doody RS, Inbody S

American Academy of Neurology (AAN)
43^rd Annual Meeting in Boston, Mass. (April 21-27, 1991)

• The alien hand and related signs.
  

  Doody RS, Jankovic J

American Anthropological Association (AAA)
89^th Annual Meeting in New Orleans, La. (Nov. 27 - Dec. 2, 1990)

• Sense and nonsense: Dissemination and empiricism in practice.
  

  Doody RS

American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)
37^th Annual Meeting in Chicago, Ill. (Sept. 7-8, 1990)

• Recurrent posterior-type aphasia associated with a seizure focus.
  

  Doody RS, Hrachovy RA

American Academy of Neurology (AAN)
42^nd Annual Meeting in Miami, Fla. (April 2-4, 1990)

• Progressive nonfluent aphasia.
  

  Feher E, Doody RS, Whitehead J, Priozzolo F

American College of Cardiology (ACC)
31^st Annual Scientific Session in Atlanta, Ga. (April 25-29, 1982)

• Effects of stress management and dietary changes in treating ischemic heart disease.
  

  Ornish DM, Scherwitz LW, Doody RS, et al.